Autoimmune hemolytic anemia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
Iqra Qamar (talk | contribs) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Autoimmune hemolytic anemia}} | {{Autoimmune hemolytic anemia}} | ||
{{CMG}} {{shyam}} | {{CMG}} {{shyam}}; {{AE}} [[User:Irfan Dotani|Irfan Dotani]] | ||
==Overview== | ==Overview== | ||
There is no significant role for secondary prevention of autoimmune hemolytic anemia. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
There is no role for secondary prevention of autoimmune hemolytic anemia. However, in patients at risk for hemolytic anemia who are suspected of having active hemolysis, screening for active hemolysis can be done via assessment of [[complete blood count]] (CBC), [[lactate dehydrogenase]] (LDH), total [[bilirubin]], and [[reticulocyte]] count. | * There is no role for secondary prevention of autoimmune hemolytic anemia. | ||
* However, in patients at risk for hemolytic anemia who are suspected of having active hemolysis, screening for active hemolysis can be done via assessment of [[complete blood count]] (CBC), [[lactate dehydrogenase]] (LDH), total [[bilirubin]], and [[reticulocyte]] count.<ref name="pmid25271314">{{cite journal| author=Zanella A, Barcellini W| title=Treatment of autoimmune hemolytic anemias. | journal=Haematologica | year= 2014 | volume= 99 | issue= 10 | pages= 1547-54 | pmid=25271314 | doi=10.3324/haematol.2014.114561 | pmc=4181250 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25271314 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 21:37, 23 May 2018
|
Autoimmune hemolytic anemia Microchapters |
|
Differentiating Autoimmune hemolytic anemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune hemolytic anemia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Autoimmune hemolytic anemia secondary prevention |
|
Autoimmune hemolytic anemia secondary prevention in the news |
|
Directions to Hospitals Treating Autoimmune hemolytic anemia |
|
Risk calculators and risk factors for Autoimmune hemolytic anemia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Irfan Dotani
Overview
There is no significant role for secondary prevention of autoimmune hemolytic anemia.
Secondary Prevention
- There is no role for secondary prevention of autoimmune hemolytic anemia.
- However, in patients at risk for hemolytic anemia who are suspected of having active hemolysis, screening for active hemolysis can be done via assessment of complete blood count (CBC), lactate dehydrogenase (LDH), total bilirubin, and reticulocyte count.[1]
References
- ↑ Zanella A, Barcellini W (2014). "Treatment of autoimmune hemolytic anemias". Haematologica. 99 (10): 1547–54. doi:10.3324/haematol.2014.114561. PMC 4181250. PMID 25271314.